NEWS

Alexion gets orphan drug designation for ALXN1007

Tuesday, Aug 30, 2016

European Commission grants orphan drug designation to ALXN1007 for the treatment of patients with graft-versus-host disease (GVHD).

ALXN1007 is currently being evaluated in a phase 2 study in patients with newly diagnosed acute GI-GVHD.

 

Source : reuters.com

Other News